

REVIEW



Utilizing quorum sensing mechanisms to develop advanced strategies for disrupting oral biofilms on dental implants

Thilina Buddika and Melan Aththanayaka

Department of Biomedical Sciences, Faculty of Health Sciences, CINEC campus, Malabe, Sri Lanka

ABSTRACT

The formation of oral biofilms on dental implants presents substantial challenges in oral healthcare, leading to complications such as peri-implantitis. Quorum sensing (QS), a microbial communication mechanism, is pivotal in the development, virulence, and antibiotic resistance of biofilms in oral pathogens. This review aims to elucidate the potential of harnessing QS mechanisms to develop advanced strategies for disrupting oral biofilms on dental implants. Initially, the stages of biofilm formation and their pathogenicity are explored, with a focus on their impact on dental implants. The intricacies of QS pathways in key oral pathogens, such as *Streptococcus mutans* and *Porphyromonas gingivalis*, are then detailed, emphasizing their role in biofilm maturation and resistance. Various molecular techniques for studying QS, including genetic and biochemical methods, are examined, along with the identification and characterization of QS molecules and receptors. The review further investigates QS disruption strategies, including quorum sensing inhibitors (QSI), enzymatic degradation of QS molecules, and the use of probiotics, prebiotics, and nanotechnology-based approaches. Clinical applications of QS-based therapies are discussed, addressing their efficacy and safety, potential resistance mechanisms, and long-term effectiveness. Regulatory and ethical considerations in the development and use of QS-targeted therapies are also considered. Future directions include the integration of personalized treatment approaches based on individual microbiome profiles and exploring synergistic effects with conventional antimicrobial treatments. This review underscores the promise of QS-targeted strategies in enhancing dental implant success rates and advocates for ongoing research and interdisciplinary collaboration to translate these findings into clinical practice.

KEYWORDS

Dental implants; Oral biofilms; Peri-implantitis; Quorum sensing (QS); Quorum sensing inhibitors (QSI)

ARTICLE HISTORY

Received 4 November 2024;
Revised 5 December 2024;
Accepted 12 December 2024

Introduction

Dental implants have revolutionized the treatment of tooth loss, providing a durable and aesthetically pleasing solution. However, their long-term success is often compromised by biofilm-related complications, such as peri-implantitis, which can lead to implant failure [1-3]. Biofilms are complex microbial communities that adhere to surfaces and exhibit high resistance to conventional antimicrobial treatments as shown in Figure 1. Oral biofilms, formed by bacteria such as *Streptococcus mutans* and periodontal pathogens like *Fusobacterium nucleatum* and the "red complex" species (*Porphyromonas gingivalis*, *Tannerella forsythia*, *Treponema denticola*), are primary culprits in oral diseases like dental caries and periodontitis [1,4,5].

Quorum Sensing Mechanisms like Developed Advanced Strategies can be used to Disrupt Oral Biofilms on Dental Implants. Quorum sensing (QS) is a sophisticated bacterial communication mechanism that enables oral bacteria to coordinate their behaviour, including biofilm formation (Figure 2) [1,5]. By sensing and responding to population density through chemical signals, bacteria regulate gene expression collectively, leading to biofilm development and increased virulence. Disrupting QS signalling pathways presents a promising strategy to prevent biofilm formation and reduce pathogenicity [6]. Recent research has focused on the application of QS inhibitors to dental implants. These inhibitors can be both synthetic and natural.



Figure 1. Biofilm formation on teeth, showcasing two conditions. (A): Teeth with biofilm where visible microbial communities adhere to the teeth surface, encapsulated within an extracellular matrix. (B): Healthy teeth, characterized by clean and smooth surface [11].

Examples include carbohydrates and autoinducer analogues [1,4,7]. They have shown potential in vitro to attenuate the pathogenicity of oral biofilms. Coating dental implant surfaces with QS inhibitors has demonstrated efficacy in reducing biofilm formation and virulence of cariogenic bacteria and periodontal pathogens [1,4].

*Correspondence: Mr. Melan Aththanayaka, Department of Biomedical Sciences, Faculty of Health Sciences, CINEC campus, Malabe, Sri Lanka. email: melanaththanayaka.official@gmail.com

© 2024 The Author(s). Published by Reseapro Journals. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 2. Quorum sensing mechanism in teeth [7].

Despite these promising in vitro results, the clinical efficacy of QS inhibitors against naturally occurring polymicrobial oral biofilms remains to be fully validated. Translating these findings into successful in vivo applications is crucial for developing advanced strategies to maintain the long-term health of dental implants [1,6,4]. This review will delve into the current understanding of QS mechanisms in oral biofilms and evaluate advanced strategies that leverage QS inhibition to combat biofilm-related complications on dental implants. Additionally, it will assess the potential clinical efficacy of QS inhibitors in managing polymicrobial oral biofilms, aiming to bridge the gap between in vitro research and in vivo application.

Materials and Methodology

The literature review aimed to explore the role of quorum sensing mechanisms in developing advanced strategies for disrupting oral biofilms on dental implants. A systematic and comprehensive search was conducted in electronic databases, including PubMed, Google Scholar, Scopus, Web of Science, and ResearchGate, from inception to the most recent publications up to the date of this review. The following keywords and MeSH terms were utilized: "quorum sensing," "oral biofilms," "dental implants," "biofilm disruption," "quorum quenching," and "oral microbiome." Boolean operators (AND, OR) were employed to refine the search and capture relevant articles addressing the relationship between quorum sensing mechanisms and oral biofilm management. Studies were included based on predefined criteria to ensure the relevance and quality of the gathered literature. Peer-reviewed articles published in English only were considered. The primary focus was on in vitro and in vivo studies that investigated quorum sensing pathways in oral bacteria and their potential applications in biofilm disruption on dental implants. Additionally, studies exploring the development of quorum sensing inhibitors (QSIs) and quorum quenching (QQ) compounds were included to provide a comprehensive overview of current and emerging strategies. Inclusion criteria encompassed studies examining quorum sensing mechanisms in oral biofilms, research focusing on the impact of QSIs and QQ compounds on dental implant biofilms, and articles presenting original research, including clinical trials, laboratory experiments, and observational studies. Exclusion criteria included studies not related to quorum sensing or oral biofilms, non-original research (reviews, editorials, commentaries), articles lacking sufficient information on methodologies or

results, and studies not published in English. The initial search yielded a large number of articles, which were subsequently screened for duplicates and relevance based on titles and abstracts. Full-text articles of potentially relevant studies were then reviewed to determine their eligibility according to the inclusion and exclusion criteria. Data extraction was performed systematically, focusing on study design, methodologies, results, and conclusions regarding the role of quorum sensing in oral biofilm management on dental implants. The gathered data were analyzed to identify common themes, trends, and gaps in the current knowledge, providing a foundation for discussing future research directions and potential clinical applications.

Biofilm Formation and Pathogenicity in the Oral Cavity

The formation of oral biofilms is a multi-stage process that significantly affects oral health. The initial adhesion stage involves planktonic (free-floating) microorganisms in the oral cavity making initial contact with surfaces of tooth or dental implants, through random interactions or chemical attraction [8-10]. Once contact is made, the microbes begin to aggregate and adhere to the surface, forming a reversible attachment. The adhered microbial cells then multiply and produce an extracellular matrix, leading to the maturation stage [8,10]. This matrix, composed of extracellular polysaccharides, proteins, and DNA, provides structural integrity and protection for the biofilm. As the biofilm matures, genetic material is exchanged between the resident microbes, potentially increasing antibiotic resistance [8]. In the final dispersion stage, portions of the mature biofilm detach and disperse, releasing planktonic cells that can colonize new surfaces, allowing the biofilm to spread and proliferate to other areas of the oral cavity [6,10,12,13]. The formation of these complex, structured biofilms enhances the ability of oral pathogens to colonize surfaces, acquire nutrients, and evade host defences, contributing to the development of oral diseases like dental caries, gingivitis, and peri-implantitis (Figure 3) [8,10,14,15].




Figure 3. Biofilm formation and pathogenicity in oral cavity. (A): Stages of biofilm development. (B): Input signals and mechanisms involved in biofilm dispersal [13].

Oral biofilms are complex microbial communities primarily composed of microorganisms embedded in an extracellular matrix [16,17]. This matrix consists of both organic and inorganic materials derived from saliva, gingival crevicular fluid, and bacterial products. A significant component of this matrix is exopolysaccharides (EPS). It constitutes 50-95% of the biofilm's dry weight and plays a crucial role in maintaining its integrity and preventing desiccation [10,18,19]. The oral biofilm is home to a diverse array of over 700 different microbial species and phylotypes from nine phyla, including *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Actinobacteria*, *Spirochaetes*, and *Fusobacteria* [20,21]. Structurally, oral biofilms exhibit a three-dimensional architecture with microorganisms adhering to solid surfaces such as tooth enamel or dental implants [15,10,20,21]. The basic structural unit is the microcolony, facilitating nutrient gradients, gene exchange, and quorum sensing [17]. Supragingivally, the biofilm forms columnar microcolonies that are perpendicular to the tooth surface. These colonies are initially dominated by Gram-positive cocci but become predominantly filamentous over time [20]. Subgingivally, the biofilm consists of filamentous bacteria, with layers of *Spirochaetes*, flagellated bacteria, and bacterial aggregates resembling test-tube brushes between the biofilm and soft tissue. Periodontal pathogens such as *Tannerella forsythia*, *Fusobacterium nucleatum*, and *Spirochaetes* colonize the pre-formed biofilm, establishing microcolonies within it [20, 22,23]. Overall, oral biofilms exhibit a dynamic and intricate three-dimensional structure. This composition and architecture evolved and displayed distinct supragingival and subgingival features.

Biofilms on dental implants can lead to peri-implantitis (Figure 4). It is a destructive inflammatory condition that significantly impacts implant success, with over 25% of implants being affected after five years. This condition begins as peri-implant mucositis [24,25]. It is an inflammation of the soft tissue around the implant and can progress to peri-implantitis. Peri-implantitis affects the underlying alveolar bone. If left untreated, this progression results in bone loss and potentially implant failure [24,26,27,28]. Implants with peri-implantitis often harbour subgingival microbiota similar to those found in natural teeth with periodontitis, including periodontal pathogens like *Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola*. Quorum sensing (QS) mechanisms play a crucial role in the development and virulence of these pathogenic biofilms [24,27,28,29]. QS allows bacteria to coordinate their behaviour, forming structured biofilms that are highly resistant to host defences and antimicrobial treatments. Oral QS systems regulate biofilm formation, virulence factor secretion, and antibiotic resistance. Such as the LuxS/AI-2 system in *Streptococcus mutans* and the AgrC/AIP system in *Porphyromonas gingivalis*. Disrupting QS signalling presents a promising strategy to prevent biofilm-related complications in dental implants [1,4,6,28,30].




Figure 4. Clinical and radiographic features of peri-implantitis. (A): Clinical photograph showing inflammation, swelling and bleeding in the peri-implant soft tissues. (B): Radiographic image showing bone loss around the dental implant [26].

Quorum Sensing Mechanisms in Oral Biofilms

The key quorum sensing (QS) systems in the oral pathogens *Streptococcus mutans* and *Porphyromonas gingivalis* play crucial roles in regulating their pathogenic behaviours. In *S. mutans*, the LuxS/AI-2 system regulates biofilm formation, extracellular matrix production, acidogenicity, aciduricity, genetic transformation, and bacteriocin production [31,32]. Furthermore, the ComCDE system in *S. mutans* is activated by the competence stimulating peptide (CSP) and controls behaviours dependent on QS. Interestingly, the QS regulon in *S. mutans* can be induced by the presence of other oral pathogens like *Aggregatibacter actinomycetemcomitans* in dual-species biofilms [1,4,31,33]. The gene for the alternative sigma factor SigX is the key regulator of QS in *S. mutans*. It is significantly enriched in periodontal pockets compared to single cultures, indicating that *S. mutans* may be competent in vivo. In *P. gingivalis*, the AgrC/AIP system controls the expression of genes involved in biofilm development, proteolytic virulence factors, and antibiotic resistance. Disrupting these QS systems could be a promising strategy to attenuate the pathogenicity of oral biofilms and prevent biofilm-related diseases like dental caries and periodontitis (Figure 5) [1,4,31,33,34].




Figure 5. Quorum sensing interactions among oral biofilm bacteria [33].

QS enables synchronized bacterial behaviour, culminating in the assembly of cooperative and structured biofilms.

Moreover, QS oversees the production of virulence factors like exopolysaccharides, proteases, and toxins, thereby heightening biofilm pathogenicity. QS further contributes to biofilm resilience by inducing genes associated with antibiotic efflux pumps and persister cell formation, thus enhancing resistance to antimicrobial agents. Consequently, disrupting QS signalling emerges as a promising strategy to mitigate oral biofilm pathogenicity, offering prospects for averting biofilm-related oral afflictions such as dental caries and periodontitis [1,4,31,33,34]. In summary, QS serves as a cornerstone

mechanism enabling oral bacteria to coordinate their behaviours, form structured biofilms, produce virulence factors, and withstand antimicrobial treatments, advocating for the targeted modulation of QS pathways in combatting biofilm-associated oral infections.

Molecular Characterization of QS Pathways and Disruption Strategies

The development of advanced strategies to disrupt oral biofilms on dental implants requires a comprehensive understanding of quorum sensing (QS) mechanisms. QS is a cell-density-dependent communication system used by bacteria to coordinate various physiological activities, including biofilm formation, through the production and detection of signalling molecules known as auto-inducers [35]. This section delves into the molecular characterization of QS pathways and explores innovative strategies for disrupting these pathways to prevent and mitigate biofilm-associated infections on dental implants. Understanding QS pathways involves a multifaceted approach combining genetic, biochemical, and imaging methods. Genetic techniques include the use of mutant strains, gene knockouts, and reporter constructs to identify and study QS-regulated genes and pathways. Biochemical methods focus on the

isolation, purification, and structural elucidation of QS molecules and their receptors [36]. Imaging techniques, such as confocal laser scanning microscopy (CLSM), have been widely used to study bacterial biofilms and QS molecules [37]. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is a molecular imaging technique that allows the mapping of QS molecules in bacterial biofilms [37, 38]. These methods collectively provide insights into the complex regulatory networks governing QS and biofilm formation [36,37].

Autoinducers, the signalling molecules of quorum sensing (QS), vary among bacterial species. Gram-negative bacteria primarily use acyl-homoserine lactones (AHLs) as autoinducers, while Gram-positive bacteria typically employ oligopeptides called autoinducing peptides (AIPs) (Figure 6) [39,40]. The identification and characterization of these molecules and their receptors are crucial for understanding QS. Techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy are employed to elucidate the structures of autoinducers. Binding assays and crystallography help characterize the interactions between autoinducers and their receptors, providing targets for QS inhibition [41].




Figure 6. Autoinducers in Gram-negative and Gram-positive bacteria [40].

QS-regulated gene expression plays a pivotal role in biofilm formation. QS controls the expression of genes involved in adhesion, extracellular matrix production, and virulence [39,42, 43]. Techniques like RNA sequencing and proteomics are used to identify QS-regulated genes and proteins [42,44]. Understanding the temporal and spatial expression patterns of these genes provides insights into the stages of biofilm development, from initial attachment to mature biofilm

formation, enabling the identification of critical intervention points for disrupting biofilms [42,44].

Quorum sensing inhibitors (QSIs) represent a promising strategy for disrupting quorum sensing (QS) and biofilm formation in bacteria. Natural QSIs include plant-derived compounds, such as furanones from the red alga *Delisea pulchra* and flavonoids like luteolin from *Scutellaria*

baicalensis, which have been shown to inhibit QS in various bacterial species [45-47]. Synthetic QSIs, designed to mimic or block autoinducer signalling molecules, offer a more targeted approach. High-throughput screening and rational drug design are employed to identify and optimize synthetic QSIs, such as 5-fluorouracil derivatives and N-acyl-3-amino-5H-furanone compounds [48]. These QSIs can prevent biofilm formation, reduce virulence factor production, and enhance the effectiveness of antibiotics against resistant bacteria.

Quorum quenching enzymes can degrade or modify quorum sensing (QS) signalling molecules, disrupting QS and preventing the expression of QS-regulated behaviours like virulence and biofilm formation [49,50]. These enzymes include lactonases that break open the lactone ring of N-acyl homoserine lactone (AHL) signals, acylases that hydrolyze the amide bond, and oxidoreductases that modify the acyl chain [49,50]. Quorum quenching has been demonstrated to attenuate virulence in pathogens like *Pseudomonas aeruginosa* and *Pectobacterium* [50]. The application of these enzymes, either as therapeutic agents or surface coatings, provides a non-toxic and environmentally friendly approach to controlling bacterial biofilms [49,50]. Ongoing research focuses on engineering quorum quenching enzymes for enhanced stability and activity [49,50,51].

Probiotics and prebiotics can effectively modulate quorum sensing (QS) and biofilm formation in pathogenic bacteria. Probiotics, such as *Lactobacillus plantarum*, can interfere with QS through various mechanisms, including the production of antagonistic compounds and competition for autoinducer molecules [52,53,55]. Prebiotics, like fructooligosaccharides (FOS), can enhance the efficacy of probiotics by promoting the growth of beneficial bacteria [55]. Studies have shown that

probiotics can disrupt biofilm formation on dental implants, demonstrating their potential as a preventive strategy against pathogenic biofilms [54,55].

Nanotechnology provides innovative solutions for the targeted delivery of quorum sensing inhibitors (QSIs) to treat microbial biofilm infections. Nanoparticles can be engineered to deliver QSIs directly to the biofilm matrix, enhancing their concentration and efficacy at the site of infection. Various nanomaterials, including liposomes, polymeric nanoparticles, and metal-organic frameworks, have been explored for this purpose [56]. These nanocarriers can be functionalized with targeting ligands to ensure selective delivery to bacterial cells, minimizing off-target effects and toxicity [56,57]. For example, solid lipid nanoparticles (SLNs) loaded with QSIs have been shown to efficiently penetrate the thick mucus in cystic fibrosis patients and inhibit the virulence factor pyocyanin produced by *Pseudomonas aeruginosa*. The QSI-loaded SLNs were more effective than the free QSI in inhibiting biofilm growth [56]. Similarly, polymeric nanoparticles and metal-organic frameworks have demonstrated enhanced anti-biofilm activity compared to conventional QSI formulations [57]. The use of nanocarriers for QSI delivery represents a promising approach to combat microbial biofilm infections, which are notoriously difficult to treat due to their increased resistance to conventional antimicrobials [56,57].

Table 1 summarises a comprehensive overview of the advanced strategies for disrupting quorum sensing (QS) and biofilm formation on dental implants. Each strategy's description, techniques/tools used, advantages, and challenges/considerations are detailed, providing a clear and structured summary for researchers and clinicians.

Table 1. Overview of association between oral health and periodontal health.

Strategy	Description	Techniques/Tools Used	Advantages	Challenges/Considerations	Source
Genetic Techniques	Studying QS pathways using gene knockouts and mutant strains.	CRISPR-Cas9, transposon mutagenesis, reporter constructs	Precise targeting of QS genes	Potential off-target effects; ethical considerations	[36]
Biochemical Methods	Isolation and structural elucidation of QS molecules and receptors.	Mass spectrometry, NMR spectroscopy, binding assays	Detailed molecular insights	Complex and time-consuming	[41]
Imaging Techniques	Visualizing QS activity and biofilm architecture in situ.	Fluorescence microscopy, confocal laser scanning microscopy	Real-time monitoring	High equipment costs	[37]
Natural QS Inhibitors	Using plant-derived compounds to inhibit QS.	Extraction, purification, high-throughput screening	Low toxicity, biocompatibility	Variability in natural compound activity	[45,46]
Synthetic QS Inhibitors	Designing molecules to mimic or block autoinducers	Rational drug design, computational modeling	High specificity	Potential for resistance development	[48]
Enzymatic Degradation	Degrading QS molecules using enzymes	Engineering of lactonases, acylases, oxidoreductases	Environmentally friendly, non-toxic	Stability and activity under physiological conditions	[49,50]

Probiotics	Utilizing beneficial bacteria to interfere with QS	Selection and cultivation of probiotic strains	Enhances oral microbiome health	Ensuring colonization and survival	[52, 53]
Prebiotics	Promoting growth of beneficial bacteria to modulate QS	Identification of effective prebiotic compounds	Enhances probiotic effectiveness	Optimal dosage and formulation	[55]
Nanotechnology-Based Delivery Systems	Targeted delivery of QSIs using nanoparticles	Liposomes, polymeric nanoparticles, metal-organic frameworks	Enhanced concentration at the injection site	Potential toxicity of nanomaterials	[56]
RNA Sequencing and Proteomics	Identifying QS-regulated genes and proteins	RNA-seq, mass spectrometry-based proteomics	Comprehensive profiling	Data complexity and analysis	[42, 44]
QS-Regulated Gene Expression Analysis	Studying temporal and spatial expression patterns of QS-regulated genes	RT-qPCR, microarrays, single-cell RNA sequencing	Insight into critical biofilm stages	Requires sophisticated analysis	[42, 44]
Functional Characterization	Investigating the roles of specific QS molecules and receptors in biofilm formation	Gene cloning, site-directed mutagenesis, protein expression assays	Functional understanding of QS mechanisms	Time-consuming and labour-intensive	[39, 41]
Combination Therapies	Integrating multiple strategies for enhanced efficacy.	Combining QSIs, enzymes, probiotics, and nanocarriers	Synergistic effects	Complexity of treatment regimen	[56]
In Vivo Models	Testing QS disruption strategies in animal models.	Rodent models, oral biofilm models in vivo	Relevance to clinical settings	Ethical and logistical challenges	[50, 51]
Clinical Trials	Evaluating safety and efficacy of QS disruption strategies in humans	Phase I-III clinical trials	Direct applicability to patient care	Regulatory hurdles, high costs	[57]

Clinical Applications, Challenges, and Future Directions

This section explores the clinical applications, challenges, and future directions of QS-based therapies in the context of dental implant care, highlighting their potential to transform current treatment protocols.

Clinical integration of QS disruption strategies

Incorporating quorum sensing (QS) disruption strategies into dental treatment protocols has the potential to revolutionize the management of biofilms on dental implants. These strategies target the communication pathways of bacterial communities, thereby preventing biofilm formation and promoting biofilm dispersal. By integrating QS-based approaches with existing dental care practices, clinicians can enhance the effectiveness of implant maintenance and reduce the incidence of implant-related infections. Personalized treatment plans, tailored to individual microbiome profiles, can further optimize outcomes by addressing the unique bacterial compositions present in each patient. The synergy between QS disruption and conventional antimicrobial treatments offers a multifaceted approach that not only prevents biofilm formation but also enhances the efficacy of antimicrobial agents, leading to more robust and sustained implant health [1,4,58].

Challenges in QS-based therapeutic development

Evaluating the efficacy and safety of QS-based therapies in clinical settings is crucial for their successful implementation. Clinical trials must be conducted to assess the therapeutic potential and identify any adverse effects associated with QS disruption. One of the primary challenges is addressing potential resistance mechanisms that bacteria might develop in response to QS-targeted therapies [59,60]. Ensuring long-term effectiveness requires continuous monitoring and possibly the development of combination therapies to prevent resistance [59]. Additionally, regulatory and ethical considerations play a significant role in the development and use of QS-targeted therapies. Regulatory bodies must establish guidelines for the approval and monitoring of these novel treatments, while ethical considerations must address the potential impacts on microbial ecology and patient health [46].

Future innovations and personalized QS therapies

Emerging technologies and innovations in QS research are paving the way for advanced strategies to combat oral biofilms on dental implants. Developments in molecular biology and bioinformatics enable the identification of novel QS pathways and potential therapeutic targets [32,61]. These advancements

support the creation of more precise and effective QS inhibitors [34, 35]. Future research should focus on personalized treatment approaches, leveraging individual microbiome profiles to tailor QS disruption strategies for optimal patient outcomes [1, 64]. Furthermore, exploring the synergistic effects between QS disruption and conventional antimicrobial treatments can provide a comprehensive approach to biofilm management. As the field progresses, interdisciplinary collaboration and continued innovation will be essential in overcoming existing challenges and harnessing the full potential of QS-based therapies in clinical practice [65, 66].

Conclusion

The exploration of quorum sensing (QS) mechanisms offers a transformative approach to managing biofilm formation on dental implants, presenting a promising avenue to address persistent challenges in oral healthcare. This review underscores the intricate relationship between QS systems and biofilm pathogenicity, highlighting the potential of QS-targeted strategies to disrupt these microbial communities effectively. By delineating the molecular pathways and innovative disruption techniques, we pave the way for the development of advanced therapies that can significantly enhance the success rates of dental implants. Moreover, the integration of QS inhibitors, enzymatic degradation of QS molecules, and nanotechnology-based delivery systems represents a multifaceted approach that holds great promise for clinical applications. However, the translation of these strategies from bench to bedside requires rigorous evaluation of their efficacy, safety, and potential resistance mechanisms. Personalized treatment regimens tailored to individual microbiome profiles and synergistic approaches combining QS disruption with conventional antimicrobial therapies could revolutionize oral healthcare. As we move forward, interdisciplinary collaboration will be crucial in advancing QS research and developing robust, ethical, and regulatory frameworks for the application of these novel therapies. Continued research efforts are essential to harness the full potential of QS-targeted interventions, ultimately leading to improved patient outcomes and the long-term maintenance of dental implants. The potential of these advanced strategies to reshape the landscape of oral biofilm management calls for a concerted effort from the scientific, medical, and dental communities to translate these insights into practical, effective treatments.

Disclosure Statement

No potential conflict of interest was reported by the author.

References

1. Wright PP, Ramachandra SS. Quorum sensing and quorum quenching with a focus on cariogenic and periodontopathic oral biofilms. *Microorganisms*. 2022;10(9):1783. <https://doi.org/10.3390/microorganisms10091783>
2. Mooney JA, Pridgen EM, Manasherob R, Suh G, Blackwell HE, Barron AE, et al. Periprosthetic bacterial biofilm and quorum sensing. *J Orthop Res* 2018;36(9):2331-2339. <https://doi.org/10.1002/jor.24019>
3. Sharma M, Sharma M, Garg E. Biofilms on dental implants: A review. *Journal of Advanced Medical and Dental Sciences Research*. 2015;3(2):132.
4. Polizzi A, Donzella M, Nicolosi G, Santonocito S, Pesce P, Isola G. Drugs for the quorum sensing inhibition of oral biofilm: New frontiers and insights in the treatment of periodontitis. *Pharmaceutics*. 2022;14(12):2740. <https://doi.org/10.3390/pharmaceutics14122740>
5. Nagi M, Chapple IL, Sharma P, Kuehne SA, Hirschfeld J. Quorum sensing in oral biofilms: influence on host cells. *Microorganisms*. 2023; 11(7):1688. <https://doi.org/10.3390/microorganisms11071688>
6. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. *Antimicrob Agents Chemother*. 2011;55(6):2655-2661. <https://doi.org/10.1128/aac.00045-11>
7. Arya S, Usha R. Bioprospecting and Exploration of Phytochemicals as Quorum Sensing Inhibitors against Cariogenic Dental Biofilm. *J Pure Appl Microbiol*. 2024;18(1):100. <https://doi.org/10.22207/JPAM.18.1.10>
8. Berger D, Rakhamimova A, Pollack A, Loewy Z. Oral biofilms: development, control, and analysis. *High-throughput*. 2018;7(3):24. <https://doi.org/10.3390/ht7030024>
9. Sterzenbach T, Helbig R, Hannig C, Hannig M. Bioadhesion in the oral cavity and approaches for biofilm management by surface modifications. *Clin. Oral Investig*. 2020;24:4237-4260. <https://doi.org/10.1007/s00784-020-03646-1>
10. Abebe GM. Oral biofilm and its impact on oral health, psychological and social interaction. *Int J Oral Dent Health*. 2021;7:127. <https://doi.org/10.23937/2469-5734/1510127>
11. Berkshire Corporation. When bacterial biofilms meet magnetic microbots. *Bio-Technology, Cleanroom News*. 2019. Source from: <https://berkshire.com/when-bacterial-biofilms-meet-magnetic-microbots/>
12. Kaplan JA. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. *J Dent Res*. 2010;89(3):205-218. <https://doi.org/10.1177/0022034509359403>
13. Rumbaugh KP, Sauer K. Biofilm dispersion. *Nat Rev Microbiol*. 2020;18(10):571-586. <https://doi.org/10.1038/s41579-020-0385-0>
14. Guillen C, Forestier C, Balestrino D. Biofilm dispersal: multiple elaborate strategies for dissemination of bacteria with unique properties. *Mol Microbiol*. 2017;105(2):188-210. <https://doi.org/10.1111/mmi.13698>
15. Almufarrij MA, Junaid K, Ejaz H. Oral Biofilm: Insight into Pathogenesis and Management Strategies. *Pak J Med Health Sci*. 2020; 14(4):720-723. https://pjmhsjournal.com/2020/oct_dec/720.pdf
16. Carmello JC, de Annunzio SR, Fontana CR. Composition, Structure, and Formation of Biofilms Constituted by Periodontopathogenic Microorganisms. *Bacterial Biofilms*. 2020: 1755-2315.
17. Saini R, Saini S, Sharma S. Biofilm: A dental microbial infection. *J Nat Sc Biol Med*. 2011;2(1):71. <https://doi.org/10.4103/0976-9668.82317>
18. Do T, Devine D, Marsh PD. Oral biofilms: molecular analysis, challenges, and future prospects in dental diagnostics. *Clin Cosmet Investig Dent*. 2013;11-19. <https://doi.org/10.2147/CCIDE.S31005>
19. Bowen WH, Burne RA, Wu H, Koo H. Oral biofilms: pathogens, matrix, and polymicrobial interactions in microenvironments. *Trends Microbiol*. 2018;26(3):229-242. <https://doi.org/10.1016/j.tim.2017.09.008>
20. Zijng V, Van Leeuwen MB, Degener JE, Abbas F, Thurnheer T, Gmür R, et al. Oral biofilm architecture on natural teeth. *PloS one*. 2010;5(2):e9321. <https://doi.org/10.1371/journal.pone.0009321>
21. Rath S, Bal SC, Dubey D. Oral biofilm: development mechanism, multidrug resistance, and their effective management with novel techniques. *Rambam Maimonides Med J*. 202;12(1):e0004. <https://doi.org/10.5041/RMMJ.10428>
22. Marsh PD. Dental plaque as a biofilm and a microbial community—implications for health and disease. *BMC Oral Health*. 2006;6(1):S14. <https://doi.org/10.1186/1472-6831-6-S1-S14>
23. Sutherland IW. The biofilm matrix—an immobilized but dynamic

- microbial environment. *Trends Microbiol.* 2001;9(5):222-227. [https://doi.org/10.1016/S0966-842X\(01\)02012-1](https://doi.org/10.1016/S0966-842X(01)02012-1)
24. Belibasakis GN, Charalampakis G, Bostanci N, Stadlinger B. Peri-implant infections of oral biofilm etiology. *Biofilm-based Healthcare-associated Infections.* 2015:69-84. Springer. https://doi.org/10.1007/978-3-319-11038-7_4
25. Lähteenmäki H, Pättilä T, Pärnänen P, Räisänen I, Tervahartiala T, Gupta S, et al. aMMP-8 point-of-care-diagnostic methods and treatment modalities in periodontitis and peri-implantitis. *Expert Opin Ther Targets.* 2023;27(7):627-637. <https://doi.org/10.1080/14728222.2023.2240014>
26. Heitz-Mayfield LJ. Peri-implant mucositis and peri-implantitis: key features and differences. *Br Dent J.* 2024;236(10):791-794. <https://doi.org/10.1038/s41415-024-7402-z>
27. Blank E, Grischke J, Winkel A, Eberhard J, Kommerein N, Doll K, et al. Evaluation of biofilm colonization on multi-part dental implants in a rat model. *BMC Oral Health.* 2021;21(1):313. <https://doi.org/10.1186/s12903-021-01665-2>
28. Armellini D, Reynolds MA, Harro JM, Molly L. Biofilm Formation on Natural Teeth and Dental Implants: What is the Difference? The role of biofilms in device-related infections. 2009:109-122. Springer. https://doi.org/10.1007/978-3-540-68119-9_5
29. Dhaliwal JS, Abd Rahman NA, Ming LC, Dhaliwal SK, Knights J, Albuquerque Junior RF. Microbial biofilm decontamination on dental implant surfaces: a mini review. *Front cell infect microbiol.* 2021;11:736186. <https://doi.org/10.3389/fcimb.2021.736186>
30. Saini R. Oral biofilm and dental implants: a brief. *Natl J Maxillofac Surg.* 2011;2(2):228-229. <https://doi.org/10.4103/0975-5950.94490>
31. Senadheera D, Cvitkovitch DG. Quorum sensing and biofilm formation by *Streptococcus mutans*. *Bacterial signal transduction: networks and drug targets.* 2008:178-188. Springer. https://doi.org/10.1007/978-0-387-78885-2_12
32. Szafranski SP, Deng ZL, Tomasz J, Jarek M, Bhuij S, Rohde M, et al. Quorum sensing of *Streptococcus mutans* is activated by *Aggregatibacter actinomycetemcomitans* and by the periodontal microbiome. *BMC Genomics.* 2017;18:1-5. <https://doi.org/10.1186/s12864-017-3618-5>
33. Huang R, Li M, Gregory RL. Bacterial interactions in dental biofilm. *Virulence.* 2011;2(5):435-444. <https://doi.org/10.4161/viru.2.5.16140>
34. Muras A, Mallo N, Otero-Casal P, Pose-Rodríguez JM, Otero A. Quorum sensing systems as a new target to prevent biofilm-related oral diseases. *Oral Diseases.* 2022;28(2):307-313. <https://doi.org/10.1111/odi.13689>
35. Cagna DR, Donovan TE, McKee JR, Metz JE, Marzola R, Murphy KG, et al. Annual review of selected scientific literature: A report of the Committee on Scientific Investigation of the American Academy of Restorative Dentistry. *J Prosthet Den.* 2024;132(6):1133-1214. <https://doi.org/10.1016/j.prosdent.2024.10.014>
36. Praneenararat T, Palmer AG, Blackwell HE. Chemical methods to interrogate bacterial quorum sensing pathways. *Org Biomol Chem.* 2012;10(41):8189-8199. <https://doi.org/10.1039/C2OB26353J>
37. Kuik C, van Hoogstraten SW, Arts JJ, Honing M, Cillero-Pastor B. Matrix-assisted laser desorption/ionization mass spectrometry imaging for quorum sensing. *AMB Express.* 2024;14(1):45. <https://doi.org/10.1186/s13568-024-01703-6>
38. Van Hoogstraten SW, Kuik C, Arts JJ, Cillero-Pastor B. Molecular imaging of bacterial biofilms—a systematic review. *Crit Rev Microbiol.* 2024;50(6):971-992. <https://doi.org/10.1080/1040841X.2023.2223704>
39. Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and possibilities for its control. *Cold Spring Harb Perspect Med.* 2012;2(11):a012427. <https://perspectivesinmedicine.cshlp.org/content/2/11/a012427.short>
40. Wu L, Luo Y. Bacterial quorum-sensing systems and their role in intestinal bacteria-host crosstalk. *Front Microbiol.* 2021;12:611413. <https://doi.org/10.3389/fmicb.2021.611413>
41. Papenfort K, Bassler BL. Quorum sensing signal–response systems in Gram-negative bacteria. *Nat Rev Microbiol.* 2016;14(9):576-588. <https://doi.org/10.1038/nrmicro.2016.89>
42. Sionov RV, Steinberg D. Targeting the holy triangle of quorum sensing, biofilm formation, and antibiotic resistance in pathogenic bacteria. *Microorganisms.* 2022;10(6):1239. <https://doi.org/10.3390/microorganisms10061239>
43. Padder SA, Prasad R, Shah AH. Quorum sensing: A less known mode of communication among fungi. *Microbiol. Res.* 2018;210:51-58. <https://doi.org/10.1016/j.micres.2018.03.007>
44. Sakuragi Y, Kolter R. Quorum-sensing regulation of the biofilm matrix genes (pel) of *Pseudomonas aeruginosa*. *J Bacteriol.* 2007;189(14):5383-5386. <https://doi.org/10.1128/jb.00137-07>
45. Vashistha A, Sharma N, Nanaji Y, Kumar D, Singh G, Barnwal RP, Yadav AK. Quorum sensing inhibitors as Therapeutics: Bacterial biofilm inhibition. *Bioorg. Chem.* 2023;136:106551. <https://doi.org/10.1016/j.bioorg.2023.106551>
46. Zhou L, Zhang Y, Ge Y, Zhu X, Pan J. Regulatory mechanisms and promising applications of quorum sensing-inhibiting agents in control of bacterial biofilm formation. *Front Microbiol.* 2020;11:589640. <https://doi.org/10.3389/fmicb.2020.589640>
47. Escobar-Muciño E, Arenas-Hernández MM, Luna-Guevara ML. Mechanisms of Inhibition of Quorum Sensing as an Alternative for the Control of *E. coli* and *Salmonella*. *Microorganisms.* 2022;10(5):884. <https://doi.org/10.3390/microorganisms10050884>
48. Naga NG, El-Badan DE, Ghanem KM, Shaaban MI. It is the time for quorum sensing inhibition as alternative strategy of antimicrobial therapy. *Cell Commun Signal.* 2023;21(1):1-4. <https://doi.org/10.1186/s12964-023-01154-9>
49. Sikdar R, Elias M. Quorum quenching enzymes and their effects on virulence, biofilm, and microbiomes: a review of recent advances. *Expert Rev Anti Infect Ther.* 2020;18(12):1221-1233. <https://doi.org/10.1080/14787210.2020.1794815>
50. Chen F, Gao Y, Chen X, Yu Z, Li X. Quorum quenching enzymes and their application in degrading signal molecules to block quorum sensing-dependent infection. *Int J Mol Sci.* 2013;14(9):17477-500. <https://doi.org/10.3390/ijms140917477>
51. Vogel J, Quax WJ. Enzymatic quorum quenching in biofilms. In *Quorum Sensing.* 2019:173-193. Academic Press. <https://doi.org/10.1016/B978-0-12-814905-8.00007-1>
52. Tomé AR, Carvalho FM, Teixeira-Santos R, Burmølle M, Mergulhão FJ, Gomes LC. Use of probiotics to control biofilm formation in food industries. *Antibiotics.* 2023;12(4):754. <https://doi.org/10.3390/antibiotics12040754>
53. Salman MK, Abuqwider J, Mauriello G. Anti-quorum sensing activity of probiotics: the mechanism and role in food and gut health. *Microorganisms.* 2023;11(3):793. <https://doi.org/10.3390/microorganisms11030793>
54. Barzegari A, Kheyrolahzadeh K, Hosseiniyan Khatibi SM, Sharifi S, Memar MY, Zununi Vahed S. The battle of probiotics and their derivatives against biofilms. *Infect Drug Resist.* 2020;13:659-672. <https://doi.org/10.2147/IDR.S232982>
55. Al-Saafin BA, Al-Bakri AG, Abdelrazig S, Dahabiyeh LA. Investigating the effect of the probiotic *Lactobacillus plantarum* and the prebiotic fructooligosaccharides on *Pseudomonas aeruginosa* metabolome, virulence factors and biofilm formation as potential quorum sensing inhibitors. *Microb Pathog.* 2023;177:106057. <https://doi.org/10.1016/j.micpath.2023.106057>
56. Dos Santos Ramos MA, Da Silva PB, Spósito L, De Toledo LG, Bonifacio BV, et al. Nanotechnology-based drug delivery systems for control of microbial biofilms: a review. *Int J Nanomedicine.* 2018;13:1179-1213. <https://doi.org/10.2147/IJN.S146195>
57. Di Stefano A. Nanotechnology in targeted drug delivery. *Int J Mol Sci.* 2023;24(9):8194. <https://doi.org/10.3390/ijms24098194>
58. Basavaraju M, Sisnity VS, Palaparthi R, Addanki PK. Quorum quenching: signal jamming in dental plaque biofilms. *J Dent Sci.* 2016;11(4):349-352. <https://doi.org/10.1016/j.jds.2016.02.002>

59. Wang J, Lu X, Wang C, Yue Y, Wei B, Zhang H, et al. Research Progress on the Combination of Quorum-Sensing Inhibitors and Antibiotics against Bacterial Resistance. *Molecules*. 2024;29(7):1674. <https://doi.org/10.3390/molecules29071674>
60. Jiang Q, Chen J, Yang C, Yin Y, Yao K. Quorum sensing: a prospective therapeutic target for bacterial diseases. *Biomed Res Int*. 2019;2019(1):2015978. <https://doi.org/10.1155/2019/2015978>
61. Novak EA, Shao H, Daep CA, Demuth DR. Autoinducer-2 and QseC control biofilm formation and in vivo virulence of *Aggregatibacter actinomycetemcomitans*. *Infect Immun*. 2010;78(7):2919-2926. <https://doi.org/10.1128/iai.01376-09>
62. Imbrono AV, Marcelino SL, Grande SR, Nunes FD, Romito GA. Detection of human cytomegalovirus and Epstein-Barr virus in coronary atherosclerotic tissue. *Braz J Microbiol*. 2010;41:563-566. <https://doi.org/10.1590/S1517-83822010000300004>
63. Rasmussen TB, Manefield M, Andersen JB, Eberl L, Anthoni U, Christophersen C, et al. How *Delisea pulchra* furanones affect quorum sensing and swarming motility in *Serratia liquefaciens* MG1. *Microbiology*. 2000;146(12):3237-3244. <https://doi.org/10.1099/00221287-146-12-3237>
64. Bach TB, Jensen AA, Petersen JG, Sørensen TE, Della Volpe S, Liu J, et al. Exploration of the molecular architecture of the orthosteric binding site in the $\alpha 4\beta 2$ nicotinic acetylcholine receptor with analogs of 3-(dimethylamino) butyl dimethylcarbamate (DMABC) and 1-(pyridin-3-yl)-1, 4-diazepane. *Eur J Med Chem*. 2015;102:425-444. <https://doi.org/10.1016/j.ejmech.2015.07.024>
65. Novick RP, Geisinger E. Quorum sensing in staphylococci. *Annu Rev Genet*. 2008;42(1):541-564. <https://doi.org/10.1146/annurev.genet.42.110807.091640>
66. Kalia VC. Quorum sensing inhibitors: an overview. *Biotechnol Adv*. 2013;31(2):224-245. <https://doi.org/10.1016/j.biotechadv.2012.10.004>